rutin and Varicose-Veins

The aim of this study was the evaluation of the effects of Venoruton (HR) on the prevention and control of flight microangiopathy and edema in subjects with varicose veins flying for more than 7 hours. A group of 80 patients with varicose veins, edema, and initial skin alterations due to chronic venous hypertension were included. Measurements of skin laser Doppler (LDF) resting flux (RF), PO2 and rate of ankle swelling (RAS), were made before and after the flights (within 2 hours before the flights and within 2 hours after the flights). The length of the flights was between 7 and 9 hours; all seats were in coach class. The two groups (treatment and control) were comparable for age and sex distribution. The variation (decrease) in PO2 was significant in both groups. In subjects treated with HR the decrease in PO2 was smaller (p < 0.05). The decrease in LDF-RF was significant in both groups with a higher flux at the end of the flight in the treated subjects (p < 0.05). The venoarteriolar response was decreased at the end of the flights. The decrease was less evident in the treatment group (p < 0.05). The increase in RAS was significant in the control group while it was limited in the HR group. In conclusion, HR is useful for reducing the increased capillary filtration and in controlling edema in patients with chronic venous disease in long-haul flights. HR is effective to control flight microangiopathy associated with edema.

Topics: Adult; Aerospace Medicine; Ankle; Edema; Female; Humans; Hydroxyethylrutoside; Hypertension; Male; Microcirculation; Oxygen; Partial Pressure; Skin; Time Factors; Treatment Outcome; Ultrasonography; Varicose Veins; Vasoconstrictor Agents; Venous Insufficiency

This study evaluated the effects of HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides) on the prevention and control of flight microangiopathy, and particularly on edema, in subjects with varicose veins flying for more than 7 hours. Forty patients with varicose veins, edema, and initial skin alterations due to chronic venous hypertension were included. Measurements of skin laser Doppler flowmetry resting flux, Po(2) and rate of ankle swelling, were made before and after the flights (within 4 hours before the flights and within 2 hours after the flights). The length of the flights was between 7 and 9 hours; all seats were in coach class. The 2 groups were comparable for distribution. The variation of Po(2) was significant in both groups. However, in subjects treated with HR, the decrease in Po(2) was smaller (P < 0.05). The decrease in laser Doppler flowmetry resting flux was also significant in both groups, with a higher flux at the end of the control period in the treated subjects (P < 0.05). The venoarteriolar response progressively decreased at 7 and 9 hours. The decrease was less evident in the treatment group (P < 0.05). The rate of ankle swelling was progressively increased in the control group; the increase was not significant in the HR group. In long-haul flights, HR is useful for reducing the increased capillary filtration and in controlling edema in patients with venous hypertension and is effective in controlling perfusion disorders and microangiopathy, particularly swelling and edema, due to flights.

Topics: Adult; Aerospace Medicine; Aircraft; Ankle; Edema; Female; Humans; Hydroxyethylrutoside; Laser-Doppler Flowmetry; Male; Microcirculation; Prospective Studies; Travel; Varicose Veins; Vasoconstrictor Agents

The aim of this study was to demonstrate whether HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides), was effective in improving levels of plasma free radicals (PFRs) in patients with chronic venous insufficiency (CVI) and venous microangiopathy. Patients were randomized into the treatment group, which received oral HR (1g sachets, twice daily, for 4 weeks), and a placebo group, which received comparable placebo. Below-knee Sigvaris stockings were used during the study. PFRs were measured with the D-Rom test at the finger and at a vein of the leg in an area of CVI. The mean age of included subjects was 46 years (SD 11) in the treatment group (20 patients; 6 females) and 46.4 (SD 8) in the placebo group (20 patients; 7 females). There were no differences between placebo and treatment groups at inclusion in age and sex distribution and in parameters indicating venous hypertension. The decrease of PFRs levels in the treatment group was significant, both at the finger and in the distal blood taken in areas of CVI. There there were no significant changes in the control group. In areas of venous hypertension, PFRs values were on average higher than at the finger (systemic) level (P < 0.05). In parallel with the progressive decrease in PFRs associated with treatment, the analogue score was significantly decreased at 2 (P < 0.05) and 4 weeks (P < 0.02) in the HR group. No changes were observed in the placebo group. No adverse effects were observed. In conclusion, HR treatment is effective in decreasing both the systemic and local values of PFRs and therefore may have a positive effect on the evolution of CVI.

Topics: Adult; Female; Free Radicals; Humans; Hydroxyethylrutoside; Hypertension; Male; Middle Aged; Placebos; Prospective Studies; Skin Ulcer; Treatment Outcome; Varicose Veins; Vascular Diseases; Venous Insufficiency

The present study was designed to compare the safety and efficacy of a combination of Ruscus aculeatus, hesperidin methyl chalcone and ascorbic acid (CYCLO 3 FORT) versus that of hydroxyethyl rutoside in the treatment of chronic venous lymphatic insufficiency.. This open-label, randomised multicentre study was conducted on outpatients treated for 90 days. The patients were from three different regions of Argentina. Eighty patients, men and women, 30 to 70 years of age, with symptoms of chronic venous lymphatic insufficiency, i.e. heavy, tired, swollen, or painful legs were enrolled and assigned to two groups: one group treated with CYCLO 3 FORT, the other with rutoside. The symptoms were assessed at baseline, and after 30, 60, and 90 days. The patient himself was asked to assess subjective symptoms, the physician measured the size of the affected limbs. The efficacy was rated on a 3-point scale and safety was evaluated by the number of side effects.. The result data show that when all patients were comparable at baseline, after 90 days, those treated with CYCLO 3 FORT reported more rapid and more complete regression of symptoms than those in the rutoside group, a statistically significant difference (p<0.01). Likewise, a significant reduction in affected limb size was observed in both groups but persisted after 90 days in the CYCLO 3 FORT group only (p<0.01).. As a conclusion : CYCLO 3 FORT was safe and more effective than rutoside in the treatment of venous lymphatic insufficiency. And the CYCLO 3 FORT efficacy is probably associated with its unique mechanism of action.

Topics: Adult; Female; Humans; Hydroxyethylrutoside; Male; Patient Satisfaction; Plant Extracts; Safety; Treatment Outcome; Varicose Veins; Vasodilator Agents; Venous Insufficiency

The aim of this study was to evaluate the effect of hydroxyethylrutosides on capillary filtration in subjects with mild to moderate venous incompetence--superficial varicose veins and/or deep venous disease and ankle oedema--using the vacuum suction chamber (VSC) device applied to the internal perimalleolar region and the wheal vanishing (WV) time. Subjects entered in to the study were randomised to receive either hydroxyethylrutosides (1 g twice daily for 4 weeks) or placebo for four weeks. The two groups entering and completing the study were comparable. Microcirculatory parameters (laser-Doppler resting flux, the venoarteriolar response, transcutaneous PO2 and PCO2) remained constant during the four week study in both groups. The WV time, which was comparable in the two groups at the beginning of the study decreased significantly [from a median 55 min (interquartile 955 min), to a median 45 minutes (interquartile 65-40 min) in the treated group, p < 0.01]. No change was observed in the WV time in the placebo group. Subjective symptoms measured with an analogue scale improved following treatment with hydroxyethylrutosides [foot oedema (p < 0.005), ankle oedema (p < 0.001), and paraesthesia (p < 0.01)]; only night cramps were reported less in patients receiving the placebo (p < 0.05). In conclusion, the WV time can be used to assess the beneficial effect of therapy on capillary filtration in subjects with mild-moderate venous hypertension, even after a short period of treatment, and before other microcirculatory parameters change. Furthermore, the changes observed in WV time correlate well with an improvement in patients symptoms.

Topics: Ankle; Capillary Permeability; Double-Blind Method; Edema; Female; Humans; Hydroxyethylrutoside; Male; Microcirculation; Treatment Outcome; Varicose Veins; Venous Insufficiency

To evaluate the clinical efficacy and pharmacologic effects of dihydroergotamine and troxerutin on varicose veins.. A double-blind, randomized, placebo-controlled parallel-group study was conducted in 53 patients with primary varicose veins. Patients received either a fixed combination of 3 mg dihydroergotamine and 300 mg troxerutin three times a day or placebo for 3 weeks. Symptomatic improvement was assessed by a self-assessment score, venocontracting effects on a varicose vein were quantified by the venous compliance technique (VCT), and changes in venous dysfunction were measured by digital photoplethysmography (DPPG).. A significant reduction (p < 0.01) of subjective symptoms was observed in both groups. Results from VCT and DPPG after the therapy with dihydroergotamine and troxerutin or placebo were not significantly different (p > 0.05) from pretreatment values. Furthermore, no significant intergroup difference was observed when the before- and after-therapy differences of values of the self-assessment scores (VCT and DPPG) were compared.. In our study, 3 weeks of treatment with a fixed drug combination of 3 mg dihydroergotamine plus 300 mg troxerutin three times a day had no measurable effect compared with placebo on any of the evaluated end points.

Topics: Adult; Dihydroergotamine; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxyethylrutoside; Male; Middle Aged; Photoplethysmography; Time Factors; Varicose Veins; Vasoconstrictor Agents

The efficacy and tolerability of O-(beta-hydroxyethyl)-rutosides (HR) in elderly patients (aged over 65 years) with chronic venous insufficiency or varicose veins was studied in a multicentre, double-blind, randomised, placebo-controlled trial. Of the 104 patients entered into the trial, data from 102 were available for analysis of tolerability and from 86 for efficacy. Treatment was for 6 months, with monthly examinations. Three different dosages were used due to slight differences in the registered dosage in various countries: (1) 250 mg 4 times daily (1 g/day), UK, n = 19 patients; (2) 300 mg 3 times daily (900 mg/day), FRG and Belgium, n = 55, and (3) 300 mg 4 times daily (1,200 mg/day), The Netherlands, n = 30. Each centre had its own placebo control group. The HR-treated group (n = 41) showed a significantly greater reduction in the total symptom score, 5.7 +/- 2.4 to 2.3 +/- 1.8, than in the placebo group, 4.4 +/- 3.0 to 3.0 +/- 2.4 (p < 0.01). Of the 5 studied symptoms there was also a significant (p < 0.05) improvement in leg cramps, heavy legs and restless legs. No significant differences between the two groups were seen for aching pains and paraesthesia. A small reduction was also seen in ankle and calf circumferences, which became significant at the end of the trial (p < 0.05). Pitting oedema of the leg (p < 0.01) and eczema of the leg (p < 0.05) also improved significantly greater than in the control group.(ABSTRACT TRUNCATED AT 250 WORDS)

Topics: Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydroxyethylrutoside; Male; Varicose Veins; Venous Insufficiency

The uptake and localisation of O-(beta-hydroxyethyl)-rutosides (HR) in the venous wall was studied in 8 patients undergoing crossectomy for a varicose long saphenous vein. The fluorescence of cross-sections of the vein wall was measured by laser scanning microscopy, based on the autofluorescence of HR. Four patients (treated group) received 2 x 1.5 g HR IV before surgery, and four (untreated patients) served as controls. Uptake of HR into the veins from treated patients was seen, with a mean fluorescence intensity of 80.9 units compared to 49.4 units in the untreated veins. The increase in fluorescence was clearly demarcated on the endothelial side of the vein wall. It is concluded that HR passes into the vascular wall, where it is localised in the endothelial and sub-endothelial areas.

Topics: Adult; Anticoagulants; Humans; Hydroxyethylrutoside; Lasers; Microscopy, Fluorescence; Middle Aged; Saphenous Vein; Varicose Veins

An experimental clinical study was performed using heparan sulfate in order to ascertain the effects of the drug in the treatment of 2nd or 3rd degree varicose dilatation of the hemorrhoid plexus. Forty female patients, mean age 37 years and suffering from varicose dilatation of the hemorrhoid plexus, were enrolled in the study. The study was carried out in an open comparison with oxerutin using parallel groups with random access. After a run-in period of 3 days, 20 patients commenced treatment with 1 50 mg tablet of heparin sulfate 3 times daily, whereas the other 20 patients were given 1,500 mg oxerutin tablet again 3 times daily. Subsequently, treatment was continued at the following doses: 1 50 mg tablet of heparin sulfate twice a day, and 1,500 mg tablet of oxerutin twice a day, for a duration of two weeks. At pre-established times (before treatment, after 1 week, after 2 weeks), a standard questionnaire was filled in relating to each patient in order to evaluate the efficacy and tolerability of treatment. No adverse or undesirable effects were reported. Each participant was also put on a personalized and computerised diet with the same fibre intake. 55% of patients treated with oxerutin reported persistent moderate or intense pain caused by defecation compared to 45% of the group treated with heparan sulfate. Both drugs induced the remission of skin rash and itching. Compared to the control drug, heparan sulfate was more efficacious in relation to the normalisation of hyperemia and mucoid secretion.(ABSTRACT TRUNCATED AT 250 WORDS)

Topics: Adult; Dose-Response Relationship, Drug; Drug Evaluation; Female; Hemorrhoids; Heparitin Sulfate; Humans; Hydroxyethylrutoside; Random Allocation; Tablets; Varicose Veins

The success of treatment aimed at improving manifestations of venous insufficiency appears today to be closely linked to a therapeutic impact on blood viscosity and the macrorheological parameters upon which it depends. This double-blind placebo-controlled trial of troxerutine was designed to evaluate changes during treatment in rheological abnormalities in 60 women with vulval varicosities and venous insufficiency of the lower limbs, half in the context of premenstrual syndrome and half in pregnant women from the 4th month on. Initial examination revealed no significant difference between the treated and control groups from a clinical and rheological standpoint in the gynecological and obstetric categories. Analysis of results showed that a high dose of troxerutine was associated with a very marked improvement in symptomatic parameters by the first month of treatment with a significant correlation between clinical criteria and rheological parameters in pregnant women as well as in those with a premenstrual syndrome. These data were confirmed by excellent acceptability as well as subjective assessment by patients after 4 months' treatment at the dosage of 4 g/d.

Topics: Anticoagulants; Double-Blind Method; Female; Humans; Hydroxyethylrutoside; Leg; Pregnancy; Pregnancy Complications, Cardiovascular; Premenstrual Syndrome; Varicose Veins; Vascular Diseases; Vulvar Diseases

Topics: Dihydroergotamine; Drug Combinations; Drug Evaluation; Female; Humans; Hydroxyethylrutoside; Male; Rutin; Varicose Veins

Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Female; Humans; Hydroxyethylrutoside; Leg; Male; Middle Aged; Muscle Tonus; Muscle, Smooth; Rutin; Varicose Veins

In a double-blind trial involving 69 patients, the effect of O-(beta-hydroxyethyl) rutoside (HR)* in the treatment of varicosis of pregnancy has been investigated. The number of patients subjectively improving in the active drug group was significantly greater than in the placebo group; patients receiving HR also showed a small but significant decrease in leg circumference. Throughout the eight-week period of the trial, there were only minimal side-effects and healthy babies were delivered with good Apgar-scores.

Topics: Adult; Female; Humans; Hydroxyethylrutoside; Pregnancy; Pregnancy Complications, Cardiovascular; Varicose Veins

Topics: Adult; Aged; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Escin; Female; Humans; Hydroxyethylrutoside; Male; Middle Aged; Nylidrin; Pyridoxine; Thiamine; Varicose Veins

Topics: Adult; Aged; Clinical Trials as Topic; Coumarins; Drug Evaluation; Female; Humans; Hydroxyethylrutoside; Male; Middle Aged; Rutin; Scopoletin; Varicose Veins

The objective of the study was to estimate the association of pregnant women with varicose veins of lower extremities (VVLE) and the possible risk for adverse birth outcomes and among them different congenital abnormalities (CAs) in their children. Prospectively and medically recorded VVLE were evaluated in 332 pregnant women who delivered infants with CA (case group) and 566 pregnant women with VVLE who delivered infants without CA (control group) and matched to cases were compared in the population-based data set of the Hungarian Case-Control Surveillance System of Congenital Abnormalities, 1980-1996. About one-quarter of pregnant women had chronic VVLE while new onset VVLE occurred in the rest of pregnant women. There was no higher risk for adverse birth outcomes of pregnant women with VVLE, in fact the rate of preterm birth and low birth weight was somewhat lower than in the newborns of pregnant women without VVLE. The comparison of VVLE occurrence in pregnant women who had offspring with 21 different CA groups and in pregnant women who later delivered babies without CA showed a higher risk only for pectus excavatum, a mild CA. In conclusion, VVLE in pregnant women does not associate with obvious hazard for their fetuses.

Topics: Adult; Anticoagulants; Case-Control Studies; Congenital Abnormalities; Female; Funnel Chest; Humans; Hungary; Hydroxyethylrutoside; Infant, Newborn; Logistic Models; Male; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Prospective Studies; Retrospective Studies; Risk Factors; Varicose Veins

Topics: Anticoagulants; Coumarins; Drug Combinations; Female; Hematologic Tests; Humans; Hydroxyethylrutoside; Pregnancy; Thrombelastography; Varicose Veins; Venous Thrombosis

The uptake and localization of troxerutin, a trihydroxy-ethyl-rutoside, in the venous wall have been studied in patients undergoing long saphenous vein surgery. Troxerutin, an autofluorescent drug, is currently used to relieve oedema and subjective symptoms in patients with chronic venous insufficiency. In order to determine the localization of the troxerutin, a confocal scanning laser microscope has been used to record the fluorescence from vein cross sections. The quantified fluorescence was used as a measure of the local concentration of troxerutin. In order to reduce the effects of local variation, several images have been scanned from each specimen. Then the recorded data have been analysed to see how the fluorescence varies in the radial direction within the venous wall. Results showed that troxerutin was significantly accumulated in both inner and outer parts of the venous wall. Whereas inner wall troxerutin uptake resulted from direct diffusion through the lumen, the outer wall uptake proceeded likely from the vasa vasorum circulation.

Topics: Adult; Aged; Anticoagulants; Data Interpretation, Statistical; Diffusion; Female; Fluorescence; Histological Techniques; Humans; Hydroxyethylrutoside; Lasers; Male; Microscopy, Fluorescence; Microtomy; Middle Aged; Saphenous Vein; Varicose Veins; Vasa Vasorum; Vasoconstrictor Agents; Veins

Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Hydroxyethylrutoside; Rutin; Varicose Veins; Venous Insufficiency

Topics: Adolescent; Adult; Aged; Child; Dihydroergotamine; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxyethylrutoside; Male; Middle Aged; Rutin; Sclerosing Solutions; Varicose Veins

The flavonoid O-(beta-hydroxyethyl)-rutoside appears to have a slight inhibitory action upon the oxidative metabolism and lactate production of culured human varicose saphenous veins. The possibility that exogenous glucose would be utilized in other metabolic pathways is discussed.

Topics: Biological Transport, Active; Glucose; Glycolysis; Humans; Hydroxyethylrutoside; Kinetics; Lactates; Oxygen Consumption; Rutin; Saphenous Vein; Varicose Veins

Topics: Adult; Aged; Blood Circulation; Female; Humans; Hydroxyethylrutoside; Male; Middle Aged; Rutin; Varicose Veins; Veins

Topics: Adult; Edema; Female; Humans; Hydroxyethylrutoside; Leg; Male; Middle Aged; Rutin; Thrombophlebitis; Varicose Veins

Topics: Aerobiosis; Electrophoresis, Agar Gel; Energy Metabolism; Humans; Hydroxyethylrutoside; Isoenzymes; L-Lactate Dehydrogenase; Male; Organ Culture Techniques; Rutin; Saphenous Vein; Varicose Veins

Topics: Humans; Hydroxyethylrutoside; Rutin; Thrombophlebitis; Varicose Veins; Vascular Diseases; Veins

Topics: Humans; Hydroxyethylrutoside; Varicose Veins

Topics: Dermatitis; Drug Therapy; Erythema Nodosum; Humans; Hydroxyethylrutoside; Leg Ulcer; Ointments; Phlebitis; Rutin; Thrombosis; Varicose Veins

Topics: Capsules; Hemorrhoids; Humans; Hydroxyethylrutoside; Phlebitis; Rutin; Varicose Ulcer; Varicose Veins